49,50 Our in vivo assessments with the orallybioavailable SMARCA2/4 PROTAC degrader, AU-24118, demonstrated a favorabletolerability profile alongside significant anti-tumor efficacy in multiple SCLC-Pand MM preclinical models. The gene discussed is SMARCA2; the disease is Miyoshi myopathy.